Stat3‐siRNA inhibits the growth of gastric cancer in vitro and in vivo. (20th October 2015)

• Record Type: Journal Article
• Authors: Sun, Ying; Guo, Bao‐feng; Xu, Li‐bo; Zhong, Jia‐teng; Liu, Zhe‐wen; Liang, Hang; Wen, Nai‐yan; Yun, Wen‐jing; Zhang, Ling; Zhao, Xue‐jian
• Is Part Of: Cell biochemistry and function. Volume 33:Number 7(2015:Oct.)
• Page Start: 495
• Page End: 502
• Publication Date: 2015-10-20
• Subjects: Stat3 -- gastric cancer -- siRNA -- anti‐tumour -- apoptosis; Cytochemistry -- Periodicals; Cell metabolism -- Periodicals; Biochemistry -- Periodicals; Cytology -- Periodicals; 572
• DOI: 10.1002/cbf.3148
• Languages: English
• ISSNs: 0263-6484

Abstract

Abstract : Gastric cancer remains one of the most prevalent and lethal malignancies in the world. Despite new advances in treatment and diagnosis, patients with advanced gastric cancer are still difficult to cure resulting in a high mortality rate and poor prognosis. Signal transducer and activator of transcription 3 (Stat3) is observed aberrant in multiple tumours, including gastric cancer. Stat3 overexpression was confirmed performing a vital role in tumorigenesis. In the present study, we constructed a pSi‐Stat3 plasmid to silence Stat3 and investigated the effect of pSi‐Stat3 on cell proliferation, apoptosis and cell cycle progression in gastric cancer cell line SGC‐7901 and mice xenograft model. Downstream proteins of Stat3, including Cyclin‐D1, Survivin and Bcl‐2, were detected as well for the underlying mechanism exploration. It showed that pSi‐Stat3 can effectively silence the expression of Stat3 and inhibits the growth of gastric tumour both in vitro and in vivo significantly via cell apoptosis and cell cycle shift induction. The findings suggest that Stat3 signal pathway might be a promising therapeutic target for tumour treatment, including gastric cancer. Copyright © 2015 John Wiley & Sons, Ltd.